| Sequential bcl-2 and c-myc oncogene rearrangements associated with the clinical transformation of non-Hodgkin s lymphoma. | lymphoma, |
| High expression of the c-myc oncogene renders melanoma cells prone to lysis by natural killer cells. | skin, |
| SIRT1 activation by a c-MYC oncogenic network promotes the maintenance and drug resistance of human FLT3-ITD acute myeloid leukemia stem cells. | leukemia, |
| Aurora kinase A mediates c-Myc s oncogenic effects in hepatocellular carcinoma. | liver, |
| MicroRNA-451 induces epithelial-mesenchymal transition in docetaxel-resistant lung adenocarcinoma cells by targeting proto-oncogene c-Myc. | lung, |
| An (8;14)(q24;q11) translocation involving the T-cell receptor alpha-chain gene and the MYC oncogene 3 region in a B-cell lymphoma. | lymphoma, |
| ETV6/ARG oncoprotein confers autonomous cell growth by enhancing c-Myc expression via signal transducer and activator of transcription 5 activation in the acute promyelocytic leukemia cell line HT93A. | leukemia, |
| The N-myc proto-oncogene and IGF-II growth factor mRNAs are expressed by distinct cells in human fetal kidney and brain. | brain,kidney, |
| The long non-coding RNA PCAT-1 promotes prostate cancer cell proliferation through cMyc. | prostate, |
| Oncogene-induced liver neoplasia in transgenic mice. | liver, |
| Oncogenic c-Myc and prothymosin-alpha protect hepatocellular carcinoma cells against sorafenib-induced apoptosis. | liver, |
| Hypomethylation of the c-myc oncogene in liver cirrhosis and chronic hepatitis. | liver, |
| Oncogene expression in small-cell lung cancer cell lines and a testicular germ-cell tumor: activation of the N-myc gene and decreased RB mRNA. | testicular,lung, |
| Quantification of the c-myc oncoprotein in human glioblastoma cells and tumor tissue. | glioblastoma, |
| Involvement of c-myc oncogene in lymphoma cell lines with no detectable chromosome rearrangement of band 8q24. | lymphoma, |
| Regulation of c-fgr proto-oncogene expression in Burkitt s lymphoma cells: effect of interferon treatment and relationship to EBV status and c-myc mRNA levels. | lymphoma, |
| Data show that p32 hyaluronan binding protein (p32) is a direct transcriptional target of oncogene Myc and that high level of Myc in malignant brain cancers correlates with high expression of p32. | brain, |
| data identify c-MYC as a radiosensitive locus, implicating this oncogenic transcription factor in the aetiology of radiogenic breast cancer | breast, |
| These findings indicate that the oncogenic function of c-Myc in prostate cancer cells is regulated by 5-Lox activity, revealing a novel mechanism of 5-Lox action | prostate, |
| Molecular cytogenetic analyses of hTERC (3q26) and MYC (8q24) genes amplifications in correlation with oncogenic human papillomavirus infection in Czech patients with cervical intraepithelial neoplasia and cervical carcinomas. | cervical, |